Hypertriglyceridemia in patients with psoriasis treated with cyclosporine - 12/10/17
Abstract |
Eight patients received cyclosporine at doses of 2.0 to 7.5 mg/kg/day. Seven of these patients had increased fasting plasma triglyceride levels with cyclosporine therapy compared with pretreatment values, which peaked after 1 month of therapy. Four patients experienced elevations in fasting triglycerides, over the upper limits for age- and sex-matched controls, which were at least two times higher than their baseline values. It was strildng that all four of these patients had previously had hypertriglyceridemia while using etretinate and three of these patients had preexisting hypertriglyceridemia before both etretinate and cyclosporine therapy. Triglyceride elevation did not correlate with cyclosporine levels. Thus cyclosporine, similar to etretinate, unmasks a latent tendency for mild to moderate hypertriglyceridemia. Fasting triglyceride levels should be monitored during cyclosporine therapy, especially after 1 to 2 months of use, and in patients with preexisting increased triglycerides and/or a history of etretinate use.
Le texte complet de cet article est disponible en PDF. Supported in part by General Clinical Research Center grant RR00102 from the National Institutes of Health to the Rockefeller University Hospital, by a training grant (AR07525) from the National Institute of Health to the Laboratory for Investigative Dermatology; by the Skin Disease Society; by the Dermatology Foundation's 1989 National Psoriasis Foundation Research grant; by a grant from Ms. Susan Weil, by a grant from Squibb/ConvaTec; by a grant from Sandoz Corporation; with a general support from the Pew Trusts. |
Vol 25 - N° 4
P. 648-651 - octobre 1991 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?